A Drug Being Developed to Treat Epidermolysis Bullosa Has Been Granted Orphan Drug Status
The Boston-based biopharmaceutical company Berg LLC has announced that their experimental drug candidate BPM 31510 (ubidecarenone) has been awarded Orphan Drug designation by the US Food and Drug Administration (FDA)…